Affordable Access

deepdyve-link
Publisher Website

Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents.

Authors
  • Su, Li1
  • Tu, Ye2
  • Kong, De-Pei1
  • Chen, Da-Gui1
  • Zhang, Chen-Xi1
  • Zhang, Wan-Nian3
  • Zhuang, Chun-Lin4
  • Wang, Zhi-Bin5
  • 1 Institute of Translational Medicine, Shanghai University, Shanghai, China. , (China)
  • 2 Department of Medicine, Shanghai East Hospital, Tongji University, 200120, Shanghai, China. , (China)
  • 3 School of Pharmacy, Second Military Medical University, 200433, Shanghai, China; School of Pharmacy, Ningxia Medical University, 750004, Yinchuan, China. , (China)
  • 4 School of Pharmacy, Second Military Medical University, 200433, Shanghai, China; School of Pharmacy, Ningxia Medical University, 750004, Yinchuan, China. Electronic address: [email protected] , (China)
  • 5 School of Pharmacy, Second Military Medical University, 200433, Shanghai, China. Electronic address: [email protected] , (China)
Type
Published Article
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Publication Date
Aug 23, 2020
Volume
131
Pages
110643–110643
Identifiers
DOI: 10.1016/j.biopha.2020.110643
PMID: 32846329
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) has been widely spread in the world with a high mortality. Cytokine storm syndrome (CSS) and acute lung injury caused by SARS-CoV-2 infection severely threaten the patients. With the purpose to find effective and low-toxic drugs to mitigate CSS, entecavir and imipenem were identified to reduce TNF-α using a LPS-induced macrophage model from the anti-infective drug library. Entecavir and imipenem efficiently suppressed the release of inflammatory cytokines by partly intervention of NF-κB activity. The acute lung injury was also alleviated and the survival time was prolonged in mice. In addition, entecavir and imipenem inhibited the release of TNF-α and IL-10 in human peripheral blood mononuclear cells (hPBMCs). Collectively, we proposed that entecavir and imipenem might be candidates for the treatment of CSS. Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Report this publication

Statistics

Seen <100 times